Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR35 | Q9HC97 | 2/20 | 0.55 |
| ▸ | TSHR | P16473 | 2/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | PLAU | P00749 | 1/20 | 0.42 |
| ▸ | S100A4 | P26447 | 2/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.38 |
| ▸ | PTPRC | P08575 | 1/20 | 0.38 |
| ▸ | ERN1 | O75460 | 1/20 | 0.38 |
| ▸ | NOS1 | P29475 | 1/20 | 0.38 |
| ▸ | NOS2 | P35228 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11594465 | 0.87 | ALDH1A1 (0.48) | GPR35TSHRTDP1ALDH1A1SMN1; SMN2 | |
| SCHEMBL7096672 | 0.83 | GPR35 (0.38) | GPR35TSHRTDP1ALDH1A1SMN1; SMN2 | |
| SCHEMBL622040 | 0.82 | GPR35 (0.53) | GPR35TSHRTDP1ALDH1A1SMN1; SMN2 | |
| SCHEMBL9759846 | 0.82 | GPR35 (0.53) | GPR35TSHRTDP1ALDH1A1SMN1; SMN2 | |
| SCHEMBL7295438 | 0.82 | TSHR (0.42) | GPR35TSHRTDP1ALDH1A1SMN1; SMN2 | |
| SCHEMBL25310 | 0.81 | HSD17B10 (0.50) | GPR35TSHRTDP1ALDH1A1SMN1; SMN2 | |
| SCHEMBL1926046 | 0.80 | TSHR (0.71) | GPR35TSHRTDP1ALDH1A1SMN1; SMN2 | |
| SCHEMBL118464 | 0.80 | TSHR (0.71) | GPR35TSHRTDP1ALDH1A1SMN1; SMN2 | |
| SCHEMBL3345170 | 0.80 | TDP1 (0.48) | GPR35TSHRTDP1ALDH1A1SMN1; SMN2 | |
| SCHEMBL6212223 | 0.79 | ALDH1A1 (0.47) | GPR35TSHRTDP1ALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 562 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113121615-B | Ferrocene boracic chiral diphosphine ligand and preparation method and application thereof | 南方科技大学 | 2023-02-17 | — | — | CN | claimed |
| CN-113121615-A | Ferrocene boracic chiral diphosphine ligand and preparation method and application thereof | 南方科技大学 | 2021-07-16 | — | — | CN | claimed |
| CN-108727444-B | Synthesis method of morphine-6-beta-D-glucuronide and intermediate compound thereof | 宜昌人福药业有限责任公司 | 2020-10-23 | — | — | CN | claimed |
| CN-108727444-A | The synthetic method and its midbody compound of morphine -6- β-D-Glucose aldehydic acid glycosides | 宜昌人福药业有限责任公司 | 2018-11-02 | — | — | CN | claimed |
| US-20160237056-A1 | NOVEL SYNTHESIS ROUTES FOR PROSTAGLANDINS AND PROSTAGLANDIN INTERMEDIATES USING METATHESIS | PATHEON API SERVICES INC. | 2016-08-18 | — | — | US | claimed |
| CN-105592851-A | Novel synthesis routes for prostaglandins and prostaglandin intermediates using metathesis | PATHEON API SERVICES INC | 2016-05-18 | — | — | CN | claimed |
| WO-2015048736-A1 | NOVEL SYNTHESIS ROUTES FOR PROSTAGLANDINS AND PROSTAGLANDIN INTERMEDIATES USING METATHESIS | IRIX PHARMACEUTICALS, INC. (US) | 2015-04-02 | — | — | WO | claimed |
| WO-2014144073-A2 | AUGMENTING MOIETIES FOR ANTI-INFLAMMATORY COMPOUNDS | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2014-09-18 | — | — | WO | claimed |
| WO-2011115892-A1 | MODULATORS OF THE RETINOIC ACID RECEPTOR-RELATED ORPHAN RECEPTORS | GRIFFIN PATRICK R (US) | 2011-09-22 | — | — | WO | claimed |
| US-7884088-B2 | biocompatible oligomers such as oligochitin, oligochitosan in solvent such as dimethylsulfoxide, admixing pi complex; for drug detoxification | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2011-02-08 | — | — | US | claimed |
| EP-0080301-B1 | HERBICIDAL CYCLOHEXANE-1,3-DIONE DERIVATIVES | ICI AUSTRALIA LIMITED (AU) | 1988-08-24 | — | — | EP | claimed |
| US-4754034-A | RECORDING MATERIALS, PRESSURE SENSITIVE, THERMOREACTIVE, ELECTROCHROMIC | BAYER AKTIENGESELLSCHAFT (DE) | 1988-06-28 | — | — | US | claimed |
| EP-0180813-B1 | CHROMOGENIC 4,4-DIARYLDIHYDROCHINAZOLONES, THEIR PREPARATION AND USE | BAYER AG (DE) | 1988-06-01 | — | — | EP | claimed |
| US-4717418-A | CEREAL SELECTIVE HERBICIDES | ICI AUSTRALIA LIMITED (AU) | 1988-01-05 | — | — | US | claimed |
| EP-0082694-B1 | HERBICIDAL CYCLOHEXANE-1,3-DIONE DERIVATIVES | ICI AUSTRALIA LIMITED (AU) | 1986-07-16 | — | — | EP | claimed |
| EP-0180813-A1 | Chromogenic 4,4-diaryldihydrochinazolones, their preparation and use | BAYER AG (DE) | 1986-05-14 | — | — | EP | claimed |
| US-4578469-A | COUMARIN DYES | HOECHST AKTIENGESELLSCHAFT (DE) | 1986-03-25 | — | — | US | claimed |
| EP-0082694-A2 | Herbicidal cyclohexane-1,3-dione derivatives | ICI AUSTRALIA LIMITED (AU) | 1983-06-29 | — | — | EP | claimed |
| EP-0080301-A2 | Herbicidal cyclohexane-1,3-dione derivatives | ICI AUSTRALIA LIMITED (AU) | 1983-06-01 | — | — | EP | claimed |
| US-4314936-A | BY MEASUREM,ENT OF FLUORESENCE | YEDA RESEARCH AND DEVELOPMENT CO., LTD. (IL) | 1982-02-09 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160237056-A1 | NOVEL SYNTHESIS ROUTES FOR PROSTAGLANDINS AND PROSTAGLANDIN INTERMEDIATES USING METATHESIS | PTGES, PTGIS, PTGES2 | GPR35 2581/4885TSHR 3459/4885TDP1 4652/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.